
BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal
BioCryst Pharmaceuticals is selling the European rights and assets for its top product for $250 million, cash that the rare disease drug developer will use to pay off debt. The buyer is privately held Neopharmed Gentili. Beyond the upfront payment, the …